Eli Lilly and Company $LLY Shares Acquired by Sanders Morris Harris LLC

Key Points

• Sanders Morris Harris increased its Eli Lilly stake by 26.2% in the third quarter, bringing its holdings to 7,821 shares valued at approximately $9.2 million. Institutional investors and hedge funds collectively own 82.53% of LLY.
• Eli Lilly reported strong quarterly results, with EPS of $8.38 exceeding estimates of $6.40 and revenue rising 47.7% year over year to $22.97 billion. Analysts maintain a “Moderate Buy” consensus rating with an average price target of $1,313.43.
• The stock trades at a high valuation—about 40.6 times earnings—making continued obesity-drug growth and successful pipeline launches important. Lilly’s pipeline includes retatrutide and an oncology collaboration with Prelude Therapeutics, while upcoming earnings and clinical data could drive volatility.

Sanders Morris Harris LLC increased its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 26.2% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 7,821 shares of the company's stock after purchasing an additional 1,623 shares during the quarter. Eli Lilly and Company makes up approximately 1.2% of Sanders Morris Harris LLC's portfolio, making the stock its 19th largest position. Sanders Morris Harris LLC's holdings in Eli Lilly and Company were worth $9,203,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in LLY. BlackRock Inc. increased its stake in Eli Lilly and Company by 1.6% in the 2nd quarter. BlackRock Inc. now owns 67,540,400 shares of the company's stock valued at $81,009,981,000 after buying an additional 1,046,558 shares during the period. State Street Corp boosted its stake in shares of Eli Lilly and Company by 1.7% during the 2nd quarter. State Street Corp now owns 36,215,754 shares of the company's stock valued at $43,438,262,000 after buying an additional 605,752 shares during the period. Bank of America Corp DE acquired a new stake in shares of Eli Lilly and Company during the 2nd quarter valued at $13,522,666,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in shares of Eli Lilly and Company by 1.9% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 7,209,385 shares of the company's stock valued at $8,647,153,000 after buying an additional 137,364 shares during the period. Finally, Jennison Associates LLC grew its holdings in shares of Eli Lilly and Company by 7.9% during the 2nd quarter. Jennison Associates LLC now owns 5,461,416 shares of the company's stock valued at $6,550,587,000 after acquiring an additional 400,538 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Analysts at Erste Group raised their FY2026 EPS estimate to $36.55 from $36.45 and their FY2027 forecast to $47.30 from $47.18, reinforcing expectations for continued profit growth above consensus. Analyst earnings estimates
• Positive Sentiment: Investor commentary continues to highlight Lilly’s dominant position in diabetes and obesity treatments, strong revenue growth and a pipeline that could support further expansion beyond Zepbound. Retatrutide is viewed as a particularly important future growth opportunity ahead of the company’s October 29 earnings report. Retatrutide earnings outlook
• Positive Sentiment: Lilly is collaborating with Prelude Therapeutics to test the experimental breast-cancer drug PRT13722 in combination with established therapies. Enrollment is expected to begin in the fourth quarter, adding potential long-term oncology value to Lilly’s pipeline. Prelude and Lilly breast cancer collaboration
• Positive Sentiment: Broader oncology spending is projected to exceed $400 billion globally by 2028, creating an attractive market backdrop for Lilly’s cancer-drug development and partnerships. Cancer drug spending outlook
• Neutral Sentiment: A Phase 1 food-effect study for tersolisib represents incremental pipeline progress, but the early-stage trial is unlikely to materially affect near-term earnings or valuation. Tersolisib study update
• Negative Sentiment: Valuation remains a concern after a roughly 404% five-year rally. Lilly trades at a high earnings multiple, so the stock may need sustained obesity-drug growth and successful pipeline launches to justify its price. Investors also face near-term volatility around the upcoming earnings release and clinical data.
• Negative Sentiment: A combination treatment generated greater weight loss than Zepbound in reported findings, but discontinuation rates were substantially higher, highlighting potential tolerability and adherence challenges for next-generation obesity therapies. Obesity-drug combination results

Eli Lilly and Company Stock Performance

LLY stock opened at $1,211.08 on Thursday. The company has a quick ratio of 1.00, a current ratio of 1.35 and a debt-to-equity ratio of 1.41. The company has a market capitalization of $1.14 trillion, a price-to-earnings ratio of 40.64, a P/E/G ratio of 1.50 and a beta of 0.46. Eli Lilly and Company has a 12 month low of $783.85 and a 12 month high of $1,292.65. The firm has a 50 day moving average of $1,177.42 and a two-hundred day moving average of $1,104.28.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The company reported $8.38 EPS for the quarter, topping the consensus estimate of $6.40 by $1.98. The company had revenue of $22.97 billion for the quarter, compared to analyst estimates of $20.82 billion. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. Eli Lilly and Company's quarterly revenue was up 47.7% on a year-over-year basis. During the same quarter in the prior year, the business posted $6.31 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. As a group, equities analysts anticipate that Eli Lilly and Company will post 34.79 EPS for the current fiscal year.

Insider Buying and Selling

In other Eli Lilly and Company news, EVP Anat Hakim sold 5,000 shares of the firm's stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the transaction, the executive vice president directly owned 11,875 shares in the company, valued at $14,131,250. This trade represents a 29.63% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of the business's stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the completion of the sale, the executive vice president directly owned 54,147 shares of the company's stock, valued at $63,628,139.70. This represents a 10.72% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 13,500 shares of company stock worth $15,958,170. Corporate insiders own 0.14% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the stock. Cantor Fitzgerald upped their price target on shares of Eli Lilly and Company from $1,410.00 to $1,440.00 and gave the stock an "overweight" rating in a research note on Thursday, October 8th. Bank of America lifted their price objective on Eli Lilly and Company from $1,251.00 to $1,334.00 and gave the company a "buy" rating in a research report on Friday, July 10th. Guggenheim boosted their target price on Eli Lilly and Company from $1,273.00 to $1,284.00 and gave the company a "buy" rating in a research note on Friday, September 18th. HSBC upped their target price on Eli Lilly and Company from $850.00 to $940.00 and gave the stock a "reduce" rating in a research report on Thursday, September 10th. Finally, BMO Capital Markets reaffirmed an "outperform" rating on shares of Eli Lilly and Company in a research note on Thursday, October 1st. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $1,313.43.

About Eli Lilly and Company

Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, Indiana. Founded in 1876 by Colonel Eli Lilly, the company researches, develops, manufactures and markets medicines for a range of conditions, including diabetes, obesity, cancer, immunological disorders, neurological diseases and pain.

Its products include Mounjaro and Zepbound, which contain tirzepatide and are used for type 2 diabetes and chronic weight management, respectively. Other key medicines include Trulicity for diabetes, Verzenio for certain breast cancers, Taltz for inflammatory and autoimmune conditions, Humalog insulin, and Kisunla for early symptomatic Alzheimer's disease.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.